Alanine aminotransferase and 20-year risk of major chronic diseases and death in a healthy cohort aged 30 to 49 years

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Alanine aminotransferase and 20-year risk of major chronic diseases and death in a healthy cohort aged 30 to 49 years. / Jensen, Morten Daniel; Lauritzen, Torsten; Vilstrup, Hendrik; Jepsen, Peter.

I: Clinical epidemiology, Bind 12, 2020, s. 345-351.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{134ecb32223c40759c6e61858538b964,
title = "Alanine aminotransferase and 20-year risk of major chronic diseases and death in a healthy cohort aged 30 to 49 years",
abstract = "Purpose: Alanine aminotransferase is the most frequently used marker of liver cell injury. We examined the association between alanine aminotransferase levels and long-term absolute risks of morbidity and mortality in healthy Danish people aged 30–49 years. Patients and Methods: We divided 671 healthy participants from the Ebeltoft Health Promotion Project into four categories based on their baseline alanine aminotransferase values: low (≤10U/l), medium-low (men: 11–34U/l, women: 11–22U/l), medium-high (men: 35–69U/l, women: 23–44U/l) and high (men: ≥70U/l, women: ≥45U/l), and followed them through Danish healthcare registries for up to 20 years. We examined mortality and absolute risks of liver disease, overall cancer, ischemic heart disease, and diabetes. Results: The risk of any cancer was highest for participants with “low alanine aminotransferase” or “high alanine aminotransferase” (20-year risk: 17.2% [95% confidence interval (CI): 6.3–32.7%] and 18.2% [95% CI: 5.7–36.3%], respectively). The risk of diabetes was highest for participants with “medium-high alanine aminotransferase” or “high alanine aminotransferase” (20-year risk: 12.1% [95% CI: 7.3–18.3%] and 9.1% [95% CI: 1.6–-25.1%], respectively). Participants with “high alanine aminotransferase” had the highest 20-year risk of liver disease (20-year risk: 13.6% [95% CI: 3.4–30.9%], while it was 1.0% or less in the other groups). The chance of being alive after 20 years without having been diagnosed with liver disease, cancer, ischemic heart disease, or diabetes was lowest in the “high alanine aminotransferase” group (50% [95% CI: 28–68%]) and 72–79% in the other groups. Conclusion: Our findings suggest that persons with high or abnormally low alanine aminotransferase measurements are at increased long-term risk of several chronic diseases.",
keywords = "ALT, Cohort study, Morbidity, Mortality",
author = "Jensen, {Morten Daniel} and Torsten Lauritzen and Hendrik Vilstrup and Peter Jepsen",
year = "2020",
doi = "10.2147/CLEP.S241292",
language = "English",
volume = "12",
pages = "345--351",
journal = "Clinical Epidemiology",
issn = "1179-1349",
publisher = "Dove Medical Press Ltd.(Dovepress)",

}

RIS

TY - JOUR

T1 - Alanine aminotransferase and 20-year risk of major chronic diseases and death in a healthy cohort aged 30 to 49 years

AU - Jensen, Morten Daniel

AU - Lauritzen, Torsten

AU - Vilstrup, Hendrik

AU - Jepsen, Peter

PY - 2020

Y1 - 2020

N2 - Purpose: Alanine aminotransferase is the most frequently used marker of liver cell injury. We examined the association between alanine aminotransferase levels and long-term absolute risks of morbidity and mortality in healthy Danish people aged 30–49 years. Patients and Methods: We divided 671 healthy participants from the Ebeltoft Health Promotion Project into four categories based on their baseline alanine aminotransferase values: low (≤10U/l), medium-low (men: 11–34U/l, women: 11–22U/l), medium-high (men: 35–69U/l, women: 23–44U/l) and high (men: ≥70U/l, women: ≥45U/l), and followed them through Danish healthcare registries for up to 20 years. We examined mortality and absolute risks of liver disease, overall cancer, ischemic heart disease, and diabetes. Results: The risk of any cancer was highest for participants with “low alanine aminotransferase” or “high alanine aminotransferase” (20-year risk: 17.2% [95% confidence interval (CI): 6.3–32.7%] and 18.2% [95% CI: 5.7–36.3%], respectively). The risk of diabetes was highest for participants with “medium-high alanine aminotransferase” or “high alanine aminotransferase” (20-year risk: 12.1% [95% CI: 7.3–18.3%] and 9.1% [95% CI: 1.6–-25.1%], respectively). Participants with “high alanine aminotransferase” had the highest 20-year risk of liver disease (20-year risk: 13.6% [95% CI: 3.4–30.9%], while it was 1.0% or less in the other groups). The chance of being alive after 20 years without having been diagnosed with liver disease, cancer, ischemic heart disease, or diabetes was lowest in the “high alanine aminotransferase” group (50% [95% CI: 28–68%]) and 72–79% in the other groups. Conclusion: Our findings suggest that persons with high or abnormally low alanine aminotransferase measurements are at increased long-term risk of several chronic diseases.

AB - Purpose: Alanine aminotransferase is the most frequently used marker of liver cell injury. We examined the association between alanine aminotransferase levels and long-term absolute risks of morbidity and mortality in healthy Danish people aged 30–49 years. Patients and Methods: We divided 671 healthy participants from the Ebeltoft Health Promotion Project into four categories based on their baseline alanine aminotransferase values: low (≤10U/l), medium-low (men: 11–34U/l, women: 11–22U/l), medium-high (men: 35–69U/l, women: 23–44U/l) and high (men: ≥70U/l, women: ≥45U/l), and followed them through Danish healthcare registries for up to 20 years. We examined mortality and absolute risks of liver disease, overall cancer, ischemic heart disease, and diabetes. Results: The risk of any cancer was highest for participants with “low alanine aminotransferase” or “high alanine aminotransferase” (20-year risk: 17.2% [95% confidence interval (CI): 6.3–32.7%] and 18.2% [95% CI: 5.7–36.3%], respectively). The risk of diabetes was highest for participants with “medium-high alanine aminotransferase” or “high alanine aminotransferase” (20-year risk: 12.1% [95% CI: 7.3–18.3%] and 9.1% [95% CI: 1.6–-25.1%], respectively). Participants with “high alanine aminotransferase” had the highest 20-year risk of liver disease (20-year risk: 13.6% [95% CI: 3.4–30.9%], while it was 1.0% or less in the other groups). The chance of being alive after 20 years without having been diagnosed with liver disease, cancer, ischemic heart disease, or diabetes was lowest in the “high alanine aminotransferase” group (50% [95% CI: 28–68%]) and 72–79% in the other groups. Conclusion: Our findings suggest that persons with high or abnormally low alanine aminotransferase measurements are at increased long-term risk of several chronic diseases.

KW - ALT

KW - Cohort study

KW - Morbidity

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=85083177777&partnerID=8YFLogxK

U2 - 10.2147/CLEP.S241292

DO - 10.2147/CLEP.S241292

M3 - Journal article

C2 - 32280278

AN - SCOPUS:85083177777

VL - 12

SP - 345

EP - 351

JO - Clinical Epidemiology

JF - Clinical Epidemiology

SN - 1179-1349

ER -